BiomX Names Michael Oster as Chief Executive Officer, David Rokach Chief Financial Officer to Support Next Phase of Growth
Rhea-AI Summary
BiomX (NYSE American: PHGE) announced on March 9, 2026 the appointment of Michael Oster as Chief Executive Officer and David Rokach as Chief Financial Officer to support the company’s next growth phase. Both executives bring senior experience in M&A, corporate strategy, finance, and capital markets.
BiomX is a clinical-stage company developing natural and engineered phage therapies targeting harmful bacteria in chronic diseases; the new leaders will focus on execution, capital strategy, and investor engagement.
Positive
- Appointed Michael Oster as CEO on March 9, 2026
- Appointed David Rokach as CFO with >20 years of finance experience
- Leadership brings experience in M&A, capital markets, and investor engagement
Negative
- None.
News Market Reaction – PHGE
On the day this news was published, PHGE gained 8.96%, reflecting a notable positive market reaction. Argus tracked a peak move of +14.1% during that session. Argus tracked a trough of -11.3% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $1M to the company's valuation, bringing the market cap to $13M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
PHGE was up 18.43% while key biotech peers showed mixed to negative moves (e.g., ADAP down 17.57%, PHIO down 0.85%, APLM down 0.10%, APM down 1.15%, BIVI up 3.82%). Momentum scanner flagged only IMRN, which moved down. This pattern points to a stock-specific reaction to PHGE’s leadership changes rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 27 | Trading activity statement | Neutral | +69.5% | Company said no undisclosed developments despite unusual stock trading activity. |
| Dec 29 | Capital raise | Neutral | +3.6% | Announced $3.0M private placement to support BX011 and strategic evaluation. |
| Dec 08 | Trial discontinued | Negative | -36.9% | Discontinued BX004 Phase 2b after high adverse events and began cost cuts. |
| Nov 25 | Trial update | Negative | -18.7% | FDA device review and dosing adjustments delayed BX004 Phase 2b topline data. |
| Nov 14 | Reverse split | Negative | -15.9% | Announced 1-for-19 reverse split, sharply reducing outstanding common shares. |
Recent news with clearly negative implications (program discontinuation, reverse split, BX004 delays) coincided with sizable declines, while a neutral trading-activity statement saw a sharp upside move, suggesting occasional speculative spikes against a generally pressured backdrop.
Over the last few months, PHGE has undergone significant structural and operational shifts. In November 2025, it announced a 1-for-19 reverse split, followed by updates and then discontinuation of its BX004 Phase 2b trial, which coincided with notable share price declines. A $3.0 million private placement in December 2025 modestly lifted the stock, while a January 27, 2026 statement on unusual trading preceded a sharp rally. Today’s CEO and CFO appointments follow extensive leadership and strategic changes highlighted in recent 8-K and 10-K filings.
Regulatory & Risk Context
An effective S-3 shelf dated February 9, 2026 registers up to 5,310,933 common shares for resale tied to Series Y preferred conversions, warrant exercises, and dividend shares. Compared with 1,593,516 shares outstanding as of February 3, 2026, full usage would significantly increase share count and dilute existing holders. A related private placement of Series Y preferred stock and warrants, with a 15% annual dividend, adds structural complexity and potential future overhang.
Market Pulse Summary
The stock moved +9.0% in the session following this news. A strong positive reaction aligns with the market’s focus on leadership credibility after recent program setbacks, governance turnover, and capital structure changes. Prior news often led to declines, except for a notable spike following a January trading-activity statement. The presence of an effective shelf registering 5,310,933 shares and Series Y preferred with a 15% dividend could still weigh on sustainability if resale or conversions add meaningful supply.
AI-generated analysis. Not financial advice.
Seasoned financial leaders join BiomX to support strategic execution and advancement of the company
Oster brings extensive experience in corporate strategy, mergers and acquisitions, and operational leadership across capital-intensive industries including energy, infrastructure, and industrial sectors. Throughout his career, he has led complex transactions and built operational platforms designed to support long-term shareholder value. Currently, Oster serves as CEO and board member of Saffron Tech Ltd., an agritech company focused on innovative saffron cultivation technologies, as well as a member of the Board of Directors of BladeRanger Ltd., a publicly traded Israeli innovator in advanced drone payload systems for defense, homeland security, and solar applications.
Earlier in his career, Oster served as Senior Vice President of Mergers and Acquisitions at Alon
David Rokach joins the company as Chief Financial Officer. He brings more than two decades of experience in finance, investment management, and corporate leadership. Rokach will oversee BiomX's financial strategy, capital markets activities, accounting, and investor relations. Rokach serves as a member of the board of directors of T3 Defense Inc. since 2024. He previously served as Chief Executive Officer of Newcom Finance and Granit Investment Company, and has advised corporations and hedge funds on strategic and financial initiatives.
"The company is entering an important phase as we evaluate business opportunities and continue executing on our development strategy," said Michael Oster, CEO of BiomX. "I look forward to working closely with our team to advance our programs, maintain disciplined execution, and deliver meaningful milestones that support long-term value for our shareholders."
"My focus will be on supporting the company's strategy with disciplined financial management and a capital approach aligned with our priorities," said David Rokach, CFO of BiomX. "I look forward to working with the leadership team to strengthen engagement with the investment community and help position BiomX for sustained progress."
About BiomX
BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT ("BacteriOphage Lead to Treatment") platform to customize phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding BiomX's strategy, the advancement of its clinical programs, future development milestones, financial strategy, and potential long-term growth. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements. These risks include, but are not limited to, risks related to the Company's clinical development programs, the timing and outcome of clinical trials, regulatory approvals, the Company's ability to obtain additional funding, and other risks described in BiomX's filings with the
Contact:
Yair Ohayon
Head of Marcomm & IR
info@biomx.com
View original content:https://www.prnewswire.com/news-releases/biomx-names-michael-oster-as-chief-executive-officer-david-rokach-chief-financial-officer-to-support-next-phase-of-growth-302708067.html
SOURCE Biomx Ltd.
FAQ
Who is the new CEO of BiomX (PHGE) and when was he appointed?
What are CFO David Rokach’s responsibilities at BiomX (PHGE)?
How do the new executives affect BiomX’s clinical-stage programs (PHGE)?
Does BiomX (PHGE) expect changes to its capital strategy after the appointments?
What relevant experience does Michael Oster bring to BiomX (PHGE)?
Will the leadership changes at BiomX (PHGE) change the company’s public strategy?
